MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 79 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affaboutunlabeled
Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER. Results from the British Columbia Tissue Microarray Project
Joseph Ragaz, Kathy D. Miller, Sunil Badve, Y. Dayachko, Sally Dunn, Torsten Holm Nielsen +4 more
2004· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
3
citations
affunlabeled
Reply to J. Menczer
Laurie Elit, Gregory R. Pond, Hsien Seow
2014· letter· pl· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affaboutunlabeled
Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).
Sonia Yip, Rozelle Harvie, Andrew Martin, Katrin Marie Sjoquist, Eric Tsobanis, Yoon‐Koo Kang +14 more
2016· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affaboutunlabeled
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
Oliver Sartor, David Laidley, Frédéric Pouliot, Stephan Probst, Robert Sabbagh, Giuseppe Esposito +3 more
2021· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affunlabeled
Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Arun Azad, Karim Fizazi, Douglas Laird, Nobuaki Matsubara, Ugo De Giorgi, Consuelo Buttigliero +9 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affaboutunlabeled
Enhancing the delivery of take-home cancer therapies in Ontario.
Erin Rae, Amanda Cy Chan, Lyndee Yeung, Scott Gavura, Jessica Arias, Vishal Kukreti +1 more
2014· article· en· Journal of Clinical Oncology· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
3
citations

How this was built: Screen · Findings · About